Design Therapeutics, Inc. Financing Cash Flow
Design Therapeutics, Inc. (DSGN) reported Financing Cash Flow of $20.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $605.00K, a 67.59% increase year-over-year.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $19.93M, a 86569.57% increase year-over-year.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $25.32M, a 9526.24% increase year-over-year.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $37.00K, a 3600.00% increase year-over-year.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $25.74M, a 4917.15% increase from fiscal 2024.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $513.00K, a 29.14% decline from fiscal 2023.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $724.00K, a 208.09% increase from fiscal 2022.
- Design Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $235.00K, a 99.94% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $605.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $20.54M 10-Q · filed 2026-08-03 | $45.86M derived: sum of 3 quarters · filed 2026-08-03 | $45.89M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $19.93M 10-Q · filed 2026-04-28 | $45.25M derived: sum of 2 quarters · filed 2026-04-28 | $45.29M derived: sum of 3 quarters · filed 2026-04-28 | $45.65M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $25.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $25.35M derived: sum of 2 quarters · filed 2026-03-09 | $25.71M derived: sum of 3 quarters · filed 2026-08-03 | $25.74M 10-K · filed 2026-03-09 |
| 2025-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $398.00K derived: sum of 2 quarters · filed 2026-08-03 | $421.00K 10-Q · filed 2025-11-05 | $684.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $384.00K 10-Q · filed 2026-08-03 | $647.00K derived: sum of 3 quarters · filed 2026-08-03 | $648.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $23.00K 10-Q · filed 2026-04-28 | $286.00K derived: sum of 2 quarters · filed 2026-04-28 | $287.00K derived: sum of 3 quarters · filed 2026-04-28 | $516.00K derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $264.00K derived: sum of 2 quarters · filed 2026-03-09 | $493.00K derived: sum of 3 quarters · filed 2026-03-09 | $513.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $230.00K derived: sum of 2 quarters · filed 2025-11-05 | $250.00K 10-Q · filed 2025-11-05 | $751.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $249.00K 10-Q · filed 2025-08-07 | $750.00K derived: sum of 3 quarters · filed 2025-08-07 | $763.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-07 | $521.00K derived: sum of 2 quarters · filed 2025-05-07 | $534.00K derived: sum of 3 quarters · filed 2025-05-07 | |
| 2023-12-31 | $501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $514.00K derived: sum of 2 quarters · filed 2025-03-10 | $724.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $223.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $210.00K 10-Q · filed 2024-08-05 | |||
| 2022-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $281.00K derived: sum of 2 quarters · filed 2024-03-19 | $79.00K derived: sum of 3 quarters · filed 2024-03-19 | $235.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$51.00K derived: sum of 2 quarters · filed 2023-11-13 | $105.00K 10-Q · filed 2023-11-13 | $298.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$46.00K 10-Q · filed 2023-08-14 | $147.00K derived: sum of 3 quarters · filed 2023-08-14 | $177.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $156.00K 10-Q · filed 2023-05-09 | $349.00K derived: sum of 2 quarters · filed 2023-05-09 | $379.00K derived: sum of 3 quarters · filed 2023-05-09 | $384.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $223.00K derived: sum of 2 quarters · filed 2023-03-14 | $228.00K derived: sum of 3 quarters · filed 2023-03-14 | $379.21M 10-K · filed 2023-03-14 |
| 2021-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $35.00K derived: sum of 2 quarters · filed 2022-11-03 | $379.02M 10-Q · filed 2022-11-03 | $379.02M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $378.99M 10-Q · filed 2022-08-08 | $378.99M derived: sum of 3 quarters · filed 2022-08-08 | $378.99M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $378.98M 10-Q · filed 2022-05-09 | $378.98M derived: sum of 2 quarters · filed 2022-05-09 | $378.98M derived: sum of 3 quarters · filed 2022-05-09 | $378.98M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.00K derived: sum of 3 quarters · filed 2022-03-10 | $44.53M 10-K · filed 2022-03-10 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $44.53M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $44.53M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $44.53M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |